Glimison-VM 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscles. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, mitigating postprandial hyperglycemia. The combination targets multiple pathophysiological defects of type 2 diabetes, providing comprehensive glycemic management. Glimison-VM 1 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy with either component. It is essential to monitor blood glucose regularly to adjust therapy and minimize the risk of hypoglycemia, particularly due to Glimepiride. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, predominantly related to Metformin and Voglibose. Contraindications include renal impairment, hepatic dysfunction, and conditions predisposing to lactic acidosis. This combination should be used under medical supervision with appropriate lifestyle modifications for optimal efficacy and safety.